Wegovy maker Novo Nordisk extends losses following first-quarter results
Shares of Danish pharmaceutical giant Novo Nordisk slid 2.5% on Friday, extending a 2.7% loss on Thursday as analysts pored over the details of the firm’s first-quarter results and monitored a potential rival weight loss treatment. The company reported that sales for its blockbuster injectable weight loss treatment Wegovy, more than doubled to 9.38 billion Danish kroner ($1.4 … Read more